Overview

Price chart · mood · technical indicators

PFE

Pfizer Incstock Healthcare

Drug Manufacturers - General

$26.3315.08%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$21.97$28.75

Current: $26.33

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

PFE

+15.08%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio19.36Forward 8.98

EPS (TTM)$1.36-21.3% YoY

Profit margin12.4%HEALTHCARE

Market cap$149.77BLarge cap

Wall Street coverage

$29.00median target· current $28.16 (+3.0%)28 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 8.98
PEG ratio: 13.77
P/B: 1.73
P/S (TTM): 2.39
EV/EBITDA: 11.93

Profitability & growth

ROE (TTM): 8.9%
Operating margin: 23.9%
Revenue growth YoY: -1.2%
Dividend yield: 6.4%
Beta: 0.39

Last earnings

Feb 3, 2026 · Estimate $0.57 · Reported $0.66

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Pfizer Inc

Company profile

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: 66 HUDSON BOULEVARD EAST, NEW YORK, NY
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$149.77B

Shares outstanding$5.69B

52W high$28.75

52W low$20.87

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

PFE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

DuPont (DD) Earnings Report Expected Tomorrow

Jim Cramer on Pfizer: “If I Want Good Yield, I’ll Buy a Bond”

Intuitive Surgical Raises 2026 Procedure Guidance After a 40% EBIT Jump: Analysts Price ISRG Above $700

Dominion Energy Stock Posts Strong Q1 With Budget Cut and Turbine Cadence Accelerating

Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance

Achondroplasia Pipeline Expands as 15+ Pharma Companies Advance Targeted Therapies for Dwarfism, Finds DelveInsight | QED Therapeutics, Ascendis Pharma, Tyra Biosciences, BridgeBio

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Baron Health Care Fund Reports Roivant Sciences as Top Q1 2026 Performer

Protein degraders gain speed as Arvinas scores landmark approval

What Makes Merck & Co. (MRK) an Investment Bet?

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

New heart failure data on BridgeBio drug lands late-breaking ESC slot

FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data

Flu Vaccine Market is expected to Hit US$ 10.74 billion by 2033 |

Novo Nordisk to launch Ozempic for type 2 diabetes in US

Pfizer Scores an FDA Approval and a Patent Win in One Week. Here’s What the Stock Could Return by 2028

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

CENTRAL TRUST Co Sells 85,365 Shares of Pfizer Inc. $PFE

About Pfizer Inc

Classification

Company profile

PFE

Market Comparison

PFE Market Analysis

Overview

PFE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

DuPont (DD) Earnings Report Expected Tomorrow

Jim Cramer on Pfizer: “If I Want Good Yield, I’ll Buy a Bond”

Intuitive Surgical Raises 2026 Procedure Guidance After a 40% EBIT Jump: Analysts Price ISRG Above $700

Dominion Energy Stock Posts Strong Q1 With Budget Cut and Turbine Cadence Accelerating

Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance

Achondroplasia Pipeline Expands as 15+ Pharma Companies Advance Targeted Therapies for Dwarfism, Finds DelveInsight | QED Therapeutics, Ascendis Pharma, Tyra Biosciences, BridgeBio

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Baron Health Care Fund Reports Roivant Sciences as Top Q1 2026 Performer

Protein degraders gain speed as Arvinas scores landmark approval

What Makes Merck & Co. (MRK) an Investment Bet?

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

New heart failure data on BridgeBio drug lands late-breaking ESC slot

FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data

Flu Vaccine Market is expected to Hit US$ 10.74 billion by 2033 |

Novo Nordisk to launch Ozempic for type 2 diabetes in US

Pfizer Scores an FDA Approval and a Patent Win in One Week. Here’s What the Stock Could Return by 2028

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

CENTRAL TRUST Co Sells 85,365 Shares of Pfizer Inc. $PFE

About Pfizer Inc

Classification

Company profile

PFE

Market Comparison